Zhen Gan Xi Feng Tang (Sedate the Liver and Extinguish Wind Decoction)

Actions

Indications

Western Uses:

• What is Zhen Gan Xi Feng Tang used for in modern practice?

  In modern practice this formula is referenced for the traditional Liver-yang-rising/internal-wind pattern that overlaps with essential hypertension and the prodromal phase of cerebrovascular accident (stroke) or transient ischemic attack. Its historical description of qi and blood rushing to the head parallels how practitioners today discuss dizziness, throbbing headache, and facial flushing accompanying elevated blood pressure.

  These biomedical correlates describe the formula’s traditional use and are not a claim that it treats or prevents hypertension, stroke, or any diagnosed disease. A published systematic review of six randomized trials found it associated with blood-pressure and symptom improvement compared with antihypertensive drugs alone, but rated the included trials’ methodological quality as generally low (see research). Any suspected stroke or hypertensive emergency is a medical emergency requiring immediate professional care, not herbal self-treatment.

  Source: traditional-use correlates summarized from Bensky & Barolet, Formulas & Strategies; clinical evidence summarized in research (PMID 23573163). Reference only, not a treatment claim.

Originally Appeared In:

• Records of Heart Felt Experiences in Medicine with References to the West (Yi Xue Zhong Zhong Can Xi Lu)

Notes:

• How is Zhen Gan Xi Feng Tang different from Tian Ma Gou Teng Yin?

  Both formulas treat ascendant Liver yang generating internal wind, but Zhen Gan Xi Feng Tang is the heavier, more urgent version. Tian Ma Gou Teng Yin uses Tian Ma and Gou Teng to calm the Liver and extinguish wind for a milder, earlier-stage presentation; Zhen Gan Xi Feng Tang instead leads with large doses of heavy, descending minerals and shells (Dai Zhe Shi, Long Gu, Mu Li, plus Huai Niu Xi’s downward-guiding action) for a more severe pattern — Zhang Xichun conceived it specifically for cases approaching or following wind-stroke.

  • vs Tian Ma Gou Teng Yin: favor Zhen Gan Xi Feng Tang when the rising-yang picture is more forceful (strongly wiry-forceful pulse, marked facial flushing, a sensation of qi/blood surging to the head) or when limb heaviness/numbness or speech changes suggest impending wind-stroke.
  • vs Ling Yang Gou Teng Tang: that formula extinguishes wind generated by extreme heat within a febrile (Wen Bing) disease presenting high fever and convulsions — a different etiology from this formula’s yin-deficiency-based rising yang.

  Key modifications (from Zhang Xichun’s original text): add Shi Gao or Long Dan Cao for more pronounced heat signs; add E Jiao for more severe yin deficiency; add Dan Nan Xing or Chuan Bei Mu where phlegm signs are present; add Da Huang where constipation accompanies the rising-yang pattern.

  Source: Bensky & Barolet, Formulas & Strategies (comparison and modifications, attributed to Zhang Xichun’s original text).

Clinical Studies & Research:

• Is there modern research on Zhen Gan Xi Feng Tang?

  Yes — a mix of clinical-trial synthesis for hypertension and preclinical network-pharmacology/mechanistic work. A systematic review of six randomized controlled trials found Zhen Gan Xi Feng Decoction, alone or combined with antihypertensive drugs, associated with improved blood pressure and symptom scores compared with conventional drugs alone, though it rated the included trials’ methodological quality as generally low. More recent work has focused on identifying the formula’s bioactive constituents and their computational targets.

  • Essential hypertension (clinical synthesis): systematic review of 6 RCTs found blood-pressure and symptom benefit versus antihypertensive drugs alone, with low-quality evidence overall (PMID 23573163).
  • Antihypertensive mechanism (preclinical): plasma UPLC-MS combined with network pharmacology and molecular dynamics simulation identified absorbed constituents (e.g., liquiritigenin, caffeic acid) with stable binding to cardiovascular-pathway targets (PMID 41155608).
  • Parkinson’s disease (preclinical): network pharmacology and molecular docking proposed active constituents (including beta-sitosterol) and targets, highlighting the neuroactive ligand-receptor interaction pathway (PMID 40958250).

  Sources: PubMed 23573163; PubMed 41155608; PubMed 40958250. Research context, not a therapeutic claim; direct high-quality clinical trial evidence remains limited.